Module 2-summaries

Module 2: Common Technical Document Summaries

Module 2 provides overviews and summaries of Modules 3, 4, and 5. It includes the Quality Overall Summary, Nonclinical Overview, Clinical Overview, and detailed written/tabulated summaries.

Module 2 is where you tell the story of your drug. It summarizes everything in Modules 3, 4, and 5 into overviews and written summaries that reviewers read first.

The two sections that matter most for IND submissions: the Nonclinical Overview (section 2.4) and the Quality Overall Summary (section 2.3). The nonclinical overview is where you explain why your preclinical data supports putting your drug into humans. Get it wrong and reviewers start asking questions before they even open Module 4.

Regfo checks your nonclinical data against ICH M3(R2) requirements and helps you build the compliance narrative that goes into your Clinical Overview and summary sections.

Sections

2.1 — CTD Table of Contents

Table of contents for the CTD

2.2 — CTD Introduction

Brief introduction to the drug including pharmacological class and proposed indication

2.3 — Quality Overall Summary

Quality overall summary covering drug substance and drug product (40-80 pages for NDA)

4 sub

2.4 — Nonclinical Overview

Nonclinical overview: integrated assessment of pharmacology, PK, and toxicology (~30 pages for NDA)

2.5 — Clinical Overview

Clinical overview: benefit-risk analysis based on all clinical data (~30 pages for NDA)

2.6 — Nonclinical Written and Tabulated Summaries

Nonclinical written and tabulated summaries covering pharmacology, PK, and toxicology (100-150 pages for NDA)

7 sub

2.7 — Clinical Summary

Clinical summary: detailed summary of clinical pharmacology, efficacy, and safety (50-400 pages for NDA)

6 sub

Related Sections

m1 — Module 1: Administrative Information and Prescribing Information

Module 1 contains documents that are specific to each region. It includes administrative information such as application forms, prescribing information, and labeling. This module is NOT part of the Common Technical Document (CTD) and varies by regulatory region.

m3 — Module 3: Quality

Module 3 contains the Body of Data for drug substance (S) and drug product (P) quality information, including manufacturing, controls, characterization, and stability per ICH M4Q guidelines.

m4 — Module 4: Nonclinical Study Reports

Module 4 contains nonclinical study reports organized per ICH M4S: pharmacology (primary, secondary, safety), pharmacokinetics (ADME), and toxicology (general, genetic, carcinogenicity, reproductive).

m5 — Module 5: Clinical Study Reports

Module 5 contains clinical study reports organized per ICH M4E: biopharmaceutic studies, human PK/PD studies, efficacy and safety studies, post-marketing data, and case report forms.

Check your compliance against this section

Upload your study data and get instant gap analysis with specific regulatory citations.

Try Compliance Check